Product Description
BL-7010is a novel, non-absorbable, orally available polymer intended for the treatment of celiac disease and gluten sensitivity.
Mechanisms of Action: Gliadin Binder
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: BioLineRx
Company Location: MODI-IN L3 7177871
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Celiac Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| BL-7010.01 | P2 |
Completed |
Celiac Disease |
2014-10-01 |
2019-03-20 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|